The global biohacking market is expected to grow from an estimated US$38.05 billion in 2025 to US$216.68 billion by 2035 at a compound annual growth rate of about 19 percent during 2026-2035, according to a report by Astute Analytica. The firm said that rising consumer demand for self-tracking, personalized health optimization and longevity tools is driving growth in metabolic monitoring, wearable diagnostics and other biohacking segments led by firms such as Nightingale Health Ltd., Function (Health), Ultrahuman, and others.
According to the research, North America accounted for the largest share of market revenue in 2025, and wearables captured the biggest product segment with nearly 23 percent of total market share. The monitoring application segment generated more than 30 percent of market revenue, while research and academic institutes represented over 35 percent of end-user revenue in 2025, the report said.
Astute Analytica noted that the category is moving from early-stage hype toward structured, subscription-driven health services anchored in continuous sensing and coaching. Wearables and real-time diagnostics that deliver consumer-accessible clinical-grade data are central to this trend, the research firm said.
Major players include Nightingale Health Ltd., Function (Health), Ultrahuman, Ancestry.com LLC, Apple Inc., BehavioSec, Bulletproof 360, Dangerous Things, Fitbit Inc., HVMN Inc., InteraXon Inc., Kickstarter PBC, Modern AlkaMe, Moodmetric, NeuroSky Inc., Synbiota, The ODIN, Thync Global Inc., 23andMe inc., and others. The report highlighted that consumer interest is broadening beyond fitness to include life-stage specific health management, and that investment in biohacking technologies is expanding across hardware, software and data analytics driving personalized health outcomes.
